Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

BACKGROUND: To date, the efficacy of the androgen receptor inhibitors enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) has not been compared directly in a clinical trial setting. Indirect comparisons can be used to assess relative efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tombal, B., Sternberg, C.N., Hussain, M., Ganguli, A., Li, Y., Sandin, R., Bhadauria, H., Oh, M., Saad, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271511/
https://www.ncbi.nlm.nih.gov/pubmed/35714477
http://dx.doi.org/10.1016/j.esmoop.2022.100510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271511/
https://www.ncbi.nlm.nih.gov/pubmed/35714477
http://dx.doi.org/10.1016/j.esmoop.2022.100510

Ejemplares similares